Central nervous system drug development: An integrative biomarker approach toward individualized medicine

NeuroRx

Volumn 2, Issue 4, 2005, Pages 683-695

  Gomez Mancilla, Baltazar ^a   Marrer, E ^a   Kehren, J ^a   Kinnunen, A ^a   Imbert, G ^a   Hillebrand, R ^a   Bergstrom M ^a   Schmidt, M E ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

CNS; Drug development; Genomics; Translational medicine

Indexed keywords

ATOMOXETINE; BIOLOGICAL MARKER; CENTRAL NERVOUS SYSTEM AGENTS; NEUROLEPTIC AGENT; NEW DRUG; OLANZAPINE; RISPERIDONE;

ANIMAL CELL; BIOTECHNOLOGY; BODY WEIGHT DISORDER; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC DISEASE; CLINICAL TRIAL; DRUG COST; DRUG INDUSTRY; FAMILIAL DISEASE; GENETICS; GENOMICS; HUMAN; MEDICAL DECISION MAKING; NERVE DEGENERATION; NONHUMAN; PATHOPHYSIOLOGY; PROTEOMICS; RARE DISEASE; REGISTRATION; REVIEW; SCHIZOPHRENIA; SYMPTOMATOLOGY;

EID: 25844444638     PISSN: 15455343     EISSN: 15455351     Source Type: Journal    
DOI: 10.1602/neurorx.2.4.683     Document Type: Article

References (64)

1. Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270:467-470, 1995.
2. DeRisi J, Penland L, Brown PO, Bittner ML, Meltzer PS, Ray M, Chen Y, Su YA, Trent JM. Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat Genet 14:457-460, 1996.
3. Lockhart DJ, Dong H, Byrne MC, Follettie MT, Gallo MV, Chee MS, Mittmann M, Wang C, Kobayashi M, Horton H, Brown EL. Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat Biotechnol 14:1675-1680, 1996.
4. Watson SJ, Akil H. Gene chips and arrays revealed: a primer on their power and their uses. Biol Psychiatry 45:533-543, 1999.
5. Mimics K. Microarrays in brain research: the good, the bad and the ugly. Nat Rev Neurosci 2:444-447, 2001.
6. Barlow C, Lockhart DJ. DNA arrays and neurobiology-what's new and what's next? Curr Opin Neurobiol 12:554-561, 2002.
7. Nisenbaum LK. The ultimate chip shot: can microarray technology deliver for neuroscience? Genes Brain Behav 1:27-34, 2002.
8. Li JZ, Vawter MP, Walsh DM, Tomita H, Evans SJ, Choudary PV, Lopez JF, Avelar A, Shokoohi V, Chung T, Mesarwi O, Jones EG, Watson SJ, Akil H, Bunney WE Jr, Myers RM. Systematic changes in gene expression in postmortem human brains associated with tissue pH and terminal medical conditions. Hum Mol Genet 13:609-616, 2004.
9. Tomita H, Vawter MP, Walsh DM, Evans SJ, Choudary PV, Li J, Overman KM, Atz ME, Myers RM, Jones EG, Watson SJ, Akil H, Bunney WE Jr. Effect of agonal and postmortem factors on gene expression profile: quality control in microarray analyses of postmortem human brain. Biol Psychiatry 55:346-352, 2004.
10. Vawter MP, Evans S, Choudary P, Tomita H, Meador-Woodruff J, Molnar M, Li J, Lopez JF, Myers R, Cox D, Watson SJ, Akil H, Jones EG, Bunney WE. Gender-specific gene expression in post-mortem human brain: localization to sex chromosomes. Neuropsychopharmacology 29:373-384, 2004.
11. Reilly SC, Cossins AR, Quinn JP, Sneddon LU. Discovering genes: the use of microarrays and laser capture microdissection in pain research. Brain Res Brain Res Rev 46:225-233, 2004.
12. Neuschäfer D, Budach WE, Wanke C, Chibout SD. Evanescent resonator chips: a universal platform with superior sensitivity for fluorescence-based microarrays. Biosens Bioelectron 18:489-497, 2003.
13. Sturzebecher S, Wandinger KP, Rosenwald A, Sathyamoorthy M, Tzou A, Mattar P, Frank JA, Staudt L, Martin R, McFarland HF. Expression profiling identifies responder and non-responder phenotypes to interferon-β in multiple sclerosis. Brain 126 [Pt 6]:1419-1429, 2003.
14. Tang Y, Glauser TA, Gilbert DL, Hershey AD, Privitera MD, Picker DM, Szaflarski JP, Sharp FR. Valproic acid blood genomic expression patterns in children with epilepsy-a pilot study. Acta Neurol Scand 109:159-168, 2004.
15. Palotas A, Puskas LG, Kitajka K, Palotas M, Molnar J, Pakaski M, Janka Z, Penke B, Kaiman J. Altered response to mirtazapine on gene expression profile of lymphocytes from Alzheimer's patients. Eur J Pharmacol 497:247-254, 2004.
16. Palotas A, Puskas LG, Kitajka K, Palotas M, Molnar J, Pakaski M. Janka Z, Penke B, Kalman. The effect of citalopram on gene expression profile of Alzheimer lymphocytes. Neurochem Res 29:1563-1570, 2004.
17. Luo L, Salunga RC, Guo H, Bittner A, Joy KC, Galindo JE, Xiao H, Rogers KE, Wan JS, Jackson MR, Erlander MG. Gene expression profiles of laser-captured adjacent neuronal subtypes. Nat Med 5:117-122, 1999.
18. Lein ES, Zhao X, Gage FH. Defining a molecular atlas of the hippocampus using DNA microarray and high throughput in situ hybridization. J Neurosci 24:3879-3889, 2004.
19. Bonaventure P, Guo H, Tian B, Liu X, Bittner A, Roland B, Salunga R, Ma XJ, Kamme F, Meurers B, Bakker M, Jurzak M, Leysen JE, Erlander MG. Nuclei and subnuclei gene expression profiling in mammalian brain. Brain Res 943:38-47, 2002.
20. Segal PS, stallings NR, Lee CE, Zhao L, Socci N, Viale A, Harris TM, Soares MB, Childs G, Elmquist JK, Parker KL, Friedman JM. Use of laser-capture microdissection for the identification of marker genes for the ventromedial hypothalamic nucleus. J Neurosci 25:4181-4188, 2005.
21. Hellmich HL, Capra B, Eidson K, Garcia J, Kennedy D, Uchida T, Parsley M, Cowart J, DeWitt DS, Prough DS. Dose-dependent neuronal injury after traumatic brain injury. Brain Res 1044:144-154, 2005.
22. Dafforn A, Chen P, Deng G, Herrler M, Iglehart D, Koritala S, Lato S, Pillarisetty S, Purohit R, Wang M, Wang S, Kurn N. Linear mRNA amplification from as little as 5 ng total RNA for global gene expression analysis. Biotechniques 37:854-857, 2004.
23. Mikulowska-Mennis A, Taylor TB, Michie SA, Raja R, Horner N, Kunitake ST. High-quality RNA from cells isolated by laser-capture microdissection. Biotechniques 33:176-179, 2002.
24. Upson JJ, Stoyanova R, Cooper HS, Patriotis C, Ross EA, Boman B, Clapper ML, Knudson AG, Bellacosa A. Optimized procedures for microarray analysis of histological specimens processed by laser-capture microdissection. J Cell Physiol 201:366-373, 2004.
25. Mimics K, Pevsner J. Progress in the use of microarray technology to study the neurobiology of disease. Nat Neurosci 7:434-439, 2004.
26. Kivisäkk P, Mahad DJ, Callahan MK, Sikora K, Trebst C, Tucky B, Wujek J, Ravid R, Staugaitis SM, Lassmann H, Ransohoff RM. Expression of CCR7 in multiple sclerosis: implications for CNS immunity. Ann Neurol 55:627-638, 2004.
27. Cepok S, Jacobsen M, Schock S, Omer B, Jaekel S, Böddeker I, Oertel WH, Sommer N, Hemmer B. Patterns of cerebrospinal fluid pathology correlate with disease progression in multiple sclerosis. Brain 124:2169-2176, 2001.
28. Eap CB, Jaquenoud Sirot E, Baumann P. Therapeutic monitoring of antidepressants in the era of pharmacogenetics studies. Ther Drug Monit 26:152-155, 2004.
29. Lane HY, Chang YC, Chiu CC, Chen MI, Hsieh MH, Chang WH. Association of risperidone treatment response with a polymorphism in the 5-HT2A receptor gene. Am J Psychiatry 159:1593-1595, 2002.
30. Harrison PJ. Weight gain with antipsychotic drugs: the role of the 5-HT2C receptor (HTR2C) and other genes. Pharmacogenet Genom 15:193-194, 2005.
31. Gould TD, Husseini KM. The molecular medicine revolution and psychiatry: bridging the gap between basic neuroscience research and clinical psychiatry. J Clin Psych 65:598-604, 2004.
32. 31a. Templeman LA, Reynolds P, Arranz B. Polymorphism of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug induced weight gain in Caucasian subjects with a first episode psychotic. Pharmacogenet Genom 15:195-200, 2005.
33. Wahlund L, Blennow K. Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients. Neurosci Lett 339:99-102, 2003.
34. Andreasen N, Blennow K. b-Amyloid (Ab) protein in cerebrospinal fluid as a biomarker for Alzheimer's disease. Peptides 23:1205-1214, 2002.
35. Metha PD, Pirttilä T. Biological markers of Alzheimer's disease. Drug Dev Res 56:74-84, 2002.
36. Klyubin I, Walsh DM, Lemere CA, et al. Amyloid β protein immunotherapy neutralizes Aβ oligomers that disrupt synaptic plasticity in vivo. Nat Med 11:556-561, 2005.
37. Sobow T, Flirski M, Kloszewska I, et al. Plasma levels of Aβ peptides are altered in amnestic mild cognitive impairment but not in sporadic Alzheimer's disease. Acta Neurobiol Exp 65:117-124, 2005.
38. Jensen M, Hartmann T, Engvall B, et al. Quantification of Alzheimer amyloid b peptides ending at residues 40 and 42 by novel ELISA systems. Mol Med 6:291-302, 2000.
39. Andreasen N, Hesse C, Davidsson P, et al. Cerebrospinal fluid β-amyloid(1-42) in Alzheimer disease differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol 56:673-680, 1999.
40. Geylis V, Kourilov V, Meiner Z, Nennesmo I, Bogdanovic N, Steinitz M. Of aging: human monoclonal antibodies against amyloid-β from healthy adults. Neurobiology 26:597-606, 2004.
41. Bayer AJ, Bullock RW, Jones D, et al. Evaluation of the safety and immunogenicity of synthetic Ab42 (AN1792) in patients with AD. Neurology 64:94-101, 2005.
42. Orgogozo JS, Gilman S, Dartigues J-F, Laurent B, Fuel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology 61:46-54, 2003.
43. Hock C, Uwe Konietzko JR, Jay T, Signorell A, Müller-Tillmanns B, Lemke U, Henke K, Moritz E, Garcia E, Wollmer MA, Umbricht D, deq Uervain DJF, Hofmann M, Maddalena A, Papassotiropoulos A, Nitsch RM. Antibodies against β-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38:547-554, 2003.
44. Porstmann T, Kiessig ST. Enzyme immunoassay techniques: an overview. J Immunol Meth 150:5-21, 1992.
45. Neri D, Pini A, Nissin A. Antibodies from phage display libraries as immunological reagents. Methods Mol Biol 80:475-501, 1996.
46. Lueking A, Horn M, Eickoff H, Bussow K, Lehrach H, Walter G. Protein microarrays for gene expression and antibody screening. Anal Biochem 270:103-111, 1999.
47. Lee JW, Nordblom GD, Smith WC, Browsher RR. Validation of biomarkers as surrogates for clinical endpoints. In: Biomarkers in clinical drug development. Series: Drugs and the Pharmaceutical Sciences. Vol 132, Chapter 6, pp 119-149. Monticello, NY: Marcel Dekker Inc., 2003.
48. Katz R. Biomarkers and surrogate markers: an FDA perspective. NeuroRx 56:673-680, 2004.
49. Karimi F, Långstrom B. Synthesis of 11C-amides using [11C]carbon monoxide and in situ activated amines by palladium-mediated carboxaminations. Org Biomol Chem 1:541-546, 2003.
50. Bacskai BJ, Klunk WE, Mathis CA, Hyman BT. Imaging amyloid deposits in vivo. J Cereb Blood Flow Metab 22:1035-1041, 2002.
51. 2 receptor occupancy studies and clinical response. Br J Psychiatry 168 [Suppl 29]:40-44, 1996.
52. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 157:514-520, 2000.
53. Rabiner EA, Bhagwagar Z, Gunn RN, et al. Pindolol augmentation of selective serotonin reuptake inhibitors: PET evidence that the dose used in clinical trials is too low. Am J Psychiatry 158:2080-2082, 2001.
54. Bergström M, Hargreaves RJ, Burns HD, et al. Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Biol Psychiatry 55:1007-1012, 2004.
55. Grunder G, Yokoi F, Offord SJ, Ravert HT, Dannals RF, Salzmann JK, et al. Time course of 5-HT2A receptor occupancy in the human brain after a single oral dose of the putative antipsychotic drug MDL 100,907 measured by positron emission tomography. [Erratum 19: 161 (1998)]. Neuropsychopharmacology 17:175-185, 1997.
56. Wilson A, Schmidt M, Ginovart N, Meyer J, Houle S. Novel radiotracers for imaging the serotonin transporter by positron emission tomography, synthesis, radiosynthesis, in vitro and ex vivo evaluation of [11C]-labelled 2-(phenylthio) araalkylamines. J Med Chem 43:3103-3110, 2000.
57. Meyer JH, Wilson AA, Ginovart N, et al. Occupancy of serotonin transporters by paroxetine and citalopram during the treatment of depression: a [(11C)] DASB PET imaging study. Am J Psychiatry 158:1843-1849, 2001.
58. Hutchinson OC, Collingridge DR, Barthel H, et al. Pharmacokinetics of radiolabeled anticancer drugs for positron emission tomography. Curr Pharmaceut Design 9:917-929, 2003.
59. Hamill TG, Krause S, Ryan C, et al. Synthesis, characterization, and first successful monkey imaging studies of metabotropic glutamate receptor subtype 5 (mGluR5) PET radiotracers. Synapse 56:205-216, 2005.
60. Templeman LA, Reynolds GP, Arranz A, San L. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first episode psychosis. Pharmacogenet Genom 15:195-200, 2005.
61. Ilyin SE, Belkowski SM, Plata-Salaman CR. Biomarker discovery and validation: technologies and integrative apporaches. Trends Biotechnol 22:411-416, 2004.
62. Goodacre R, Vaidyanathan S, Dunn WB, Harrigan GG, Kell DB. Metabolomics by numbers: acquiring and understanding global metabolite data. Trends Biotechnol 22:245-252, 2004.
63. Yuan X, Desiderio DM. Proteomics analysis of human cerebrospinal fluid. J Chromatogr B Analyt Technol Biomed Life Sci 815:179-189, 2005.
64. Steel LF, Haab BB, Hanash SM. Methods of comparative proteomic profiling for disease diagnostics. J Chromatogr B Analyt Technol Biomed Life Sci 815:275-284, 2005.